載入...
The effect of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes
Patients with type 2 diabetes have a significantly increased risk of cardiovascular disease (CVD) compared to the general population—with CVD accounting for two out of every three deaths in patients with diabetes. In 2008, the FDA suggested that CVD risk should be evaluated for any new antidiabetic...
Na minha lista:
| 發表在: | Clin Cardiol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Wiley Periodicals, Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6414247/ https://ncbi.nlm.nih.gov/pubmed/30635924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23152 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|